Loading...
Loading...
Just when little old Betaville thought the dealmaking frenzy in US-listed biotechnology stocks was slowing down GlaxoSmithKline pops up with a $1.9 billion takeover of Rapt Therapeutics, a developer therapies for patients living with food allergies and inflammatory diseases.